Experimental growth shot tested for kids with rare bone disease
NCT ID NCT05845749
Summary
This early-stage study is testing whether daily injections of a medication called vosoritide can safely help children with rare genetic disorders (MPS IVA and MPS VI) grow taller. Six children aged 5-10 will receive the injections for nearly two years while researchers monitor safety and measure growth changes. Participants must already be receiving standard enzyme replacement therapy and will continue it throughout the study.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MPS IVA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCSF Benioff Children's Hospital Oakland
Oakland, California, 94609, United States
Conditions
Explore the condition pages connected to this study.